GDRX on Nasdaq

GoodRx

Logo: GoodRx, Inc., Public domain, via Wikimedia Commons5

American healthcare company

GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications.3 Its shares trade on Nasdaq under the symbol GDRX.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$796.9MRevenue, fiscal 20256
$30.4MNet income, fiscal 20256
Sep 2011Founded1

Compare with Upwork, LiveRamp or NERDWALLET, INC., or pick any stock.

  • TickerGDRX on Nasdaq1
  • Industryhealth care industry1
  • HeadquartersSanta Monica1
  • Websitewww.goodrx.com
  • Legal formDelaware corporation, privately held company1
  • Incorporated inDE7
  • Business address2701 Olympic Boulevard, Santa Monica, Ca 904047
  • Filer categoryAccelerated filer7
  • LEI25490061CWK7F0OTY2604
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 50364584

GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

11.0%Operating margin6
3.8%Net margin6
0.6%Revenue growth, 20256
4.9%Return on equity6
0.78×Debt to equity6
$164.4MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Prescription Transactions Revenue brought in 68% of the revenue GoodRx broke down this way in fiscal 2025.

  1. Prescription Transactions Revenue$544.0M668%down 6% from 2024
  2. Pharma Direct Revenue$151.4M619%up 41% from 2024
  3. Subscription Revenue$83.8M611%down 3% from 2024
  4. Other Revenue$17.7M62%down 16% from 2024
Products and services by year
Products and services202320242025
Prescription Transactions Revenue$550.7M$577.5M$544.0M
Pharma Direct Revenue$85.1M$107.2M$151.4M
Subscription Revenue$94.4M$86.5M$83.8M
Other Revenue$20.1M$21.0M$17.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development15¢$121.0M
  • Other costs78¢$619.3M
  • Income tax3¢$26.1M
  • Profit4¢$30.4M

Out of $796.9M in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending2¢$3.5M
  • Share buybacks98¢$216.4M

Out of $167.9M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.6

Financial statements

Revenue10111213146$796.9M in 2025+219% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $249.5M$249.5M20182019: $388.2M$388.2M2019+56%2020: $550.7M$550.7M2020+42%2021: $745.4M$745.4M2021+35%2022: $766.6M$766.6M2022+3%2023: $750.3M$750.3M2023−2%2024: $792.3M$792.3M2024+6%2025: $796.9M$796.9M2025+1%
Operating income10111213146$87.5M in 2025+13% since 2018
-$400.0M-$200.0M0$200.0M2018: $77.3M$77.3M20182019: $139.7M$139.7M2019+81%2020: -$275.7M-$275.7M20202021: $13.4M$13.4M20212022: $1.7M$1.7M2022−87%2023: -$27.0M-$27.0M20232024: $65.8M$65.8M20242025: $87.5M$87.5M2025+33%
Net income10111213146$30.4M in 2025−30% since 2018
-$300.0M-$200.0M-$100.0M0$100.0M2018: $43.8M$43.8M20182019: $66.0M$66.0M2019+51%2020: -$293.6M-$293.6M20202021: -$25.3M-$25.3M2021−91%2022: -$32.8M-$32.8M2022+30%2023: -$8.9M-$8.9M2023−73%2024: $16.4M$16.4M20242025: $30.4M$30.4M2025+86%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Revenue$796.9M$792.3M$750.3M
Cost of revenue, exclusive of depreciation and amortization presented separately below$57.6M$48.2M$66.9M
Product development and technology$121.0M$123.7M$135.8M
Sales and marketing$331.6M$367.1M$341.3M
General and administrative$114.0M$117.9M$125.5M
Depreciation and amortization$85.2M$69.5M$107.7M
Total costs and operating expenses$709.4M$726.5M$777.3M
Operating income (loss)$87.5M$65.8M-$27.0M
Other income (expense)$718.0K-$2.7M-$4.0M
Loss on extinguishment of debt$0-$2.1M$0
Interest income$10.9M$23.3M$32.2M
Interest expense-$42.6M-$52.9M-$56.7M
Total other expense, net-$31.0M-$34.4M-$28.6M
Income (loss) before income taxes$56.5M$31.5M-$55.6M
Income tax (expense) benefit-$26.1M-$15.1M$46.7M
Net income (loss)$30.4M$16.4M-$8.9M
Basic (in usd per share)$0.09$0.04-$0.02
Diluted (in usd per share)$0.09$0.04-$0.02
Basic (in shares)356.3M shares385.7M shares410.3M shares
Diluted (in shares)357.0M shares392.2M shares410.3M shares

Compare GoodRx with another company

Corporate structure

GoodRx sits at the top of its group. 15 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of GoodRx

  • GoodRx Santa Monica, California, United States
    • Buckeye Acquisition, LLC DBA RxNXT Subsidiary · Delaware, United States
    • flipMD, Inc. Subsidiary · Delaware, United States
    • GoodRx Care, LLC FKA HeyDoctor, LLC Subsidiary · Delaware, United States
    • GoodRx Intermediate Holdings, LLC Subsidiary · Delaware, United States
    • HealthiNation Inc. Subsidiary · Delaware, United States
    • Iodine, Inc. Subsidiary · Delaware, United States
    • Lighthouse Acquisition Corp. Subsidiary · Delaware, United States
    • Pharmacy Services, LLC Subsidiary · Delaware, United States
    • Project Cannon, LLC Subsidiary · Delaware, United States
    • RxSaver, Inc. Subsidiary · Delaware, United States
    • Scriptcycle, LLC Subsidiary · North Carolina, United States
    • ScriptDrop Acquisition, LLC Subsidiary · Delaware, United States
    • VCRx Acquisition, LLC Subsidiary · Delaware, United States
    • VitaCare Prescription Services, Inc. Subsidiary · Florida, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What GoodRx reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$326.2M6 Dec 31, 2025$253.3M6 Dec 31, 2024+28.8%
Property and equipment, before depreciation$34.6M6 Dec 31, 2025$30.9M6 Dec 31, 2024+11.9%
Accumulated depreciation$22.3M6 Dec 31, 2025$18.2M6 Dec 31, 2024+22.3%
Property and equipment, net$12.3M6 Dec 31, 2025$12.7M6 Dec 31, 2024−3.1%
Operating-lease assets (leased space)$28.8M6 Dec 31, 2025$27.8M6 Dec 31, 2024+3.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$261.8M6 Dec 31, 2025$448.3M6 Dec 31, 2024−41.6%
Stakes in other companies (equity method)$15.0M6 Dec 31, 2025$15.0M6 Dec 31, 20240%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$430.3M6 Dec 31, 2025$410.8M6 Dec 31, 2024+4.8%
Finite-lived intangibles, gross$171.9M6 Dec 31, 2025$154.0M6 Dec 31, 2024+11.6%
Accumulated amortization$107.8M6 Dec 31, 2025$101.9M6 Dec 31, 2024+5.8%
Finite-lived intangibles, net$64.1M6 Dec 31, 2025$52.1M6 Dec 31, 2024+23.0%

Properties, in its own words

Our corporate headquarters is located in Santa Monica, California, where we lease approximately 74,000 square feet

of space under a lease expiring in 2031. We also maintain smaller satellite offices across the United States. We believe that

The rest of Item 2

these facilities are sufficient for our current needs and that additional facilities will be available to accommodate our business

should they be needed.

Item 2 of the 10-K filed Feb 26, 2026.19

The story

Financial performance

GoodRx was founded in Santa Monica, California in 2011. GoodRx experienced substantial growth in net income in 2017 ($9 million), 2018 ($44 million), and 2019 ($66 million), but recorded a loss of $293.6 million in 2020 due to IPO-related expenses.

In September 2020, GoodRx went public on the Nasdaq under the ticker symbol GDRX. The company priced its initial public offering at $33 per share, above the expected range of $24 to $28, raising more than $1.1 billion at an initial valuation of approximately $12.7 billion. In the first half of 2020, the company reported revenues of $257 million and net income of $55 million.

GoodRx generated $745.4 million in revenue for the full year 2021, a 35.36% increase over 2020. During the first half of 2021, the company's share price declined by 10.7%. The decline was attributed to increased competition in online pharmacy services and slower user growth.

GoodRx reported full-year revenue of $766.6 million, with adjusted EBITDA reaching $213.5 million, exceeding guidance in the fourth quarter. GoodRx reported that 41% of prescriptions filled using its coupons were newly adherent, meaning they would not have been filled without the service.

GoodRx reported a full-year 2023 revenue of $750.3 million, a decrease of 2.1% from 2022. However, its fourth-quarter revenue increased by 7% year-over-year. GoodRx achieved an Adjusted EBITDA of $217.4 million for the year and an Adjusted EBITDA Margin of 28.6%.

In 2024, GoodRx achieved 6% revenue growth with $792.3 million for the full year and turned a net loss into a positive net income of $16.4 million. The company also demonstrated strong operational efficiency, with a 32.8% increase in full-year Adjusted EBITDA.

In Q2 2025, GoodRx reported revenue of $203.1 million, a 1.2% increase from the previous year, and a net income of $12.8 million, a significant 92% jump, which resulted in a 6.3% net income margin. However, prescription transaction revenue declined by 3% due to a decrease in monthly active consumers, but this was offset by strong 32% growth in its Pharma Manufacturer Solutions business. GoodRx also saw a 7% decrease in subscription revenue.

Mergers and acquisitions

In 2019, GoodRx acquired HeyDoctor, a telemedicine company, to integrate virtual healthcare services into the platform.

Read the full text

In 2021, a health video content producer, HealthiNation was acquired by GoodRx, which helped provide consumers with health information and offered pharmaceutical manufacturers new ways to reach relevant audiences.

In April 2022, GoodRx acquired VitaCare Prescription Services from TherapeuticsMD to strengthen its pharma manufacturer solutions business.

Partnerships

In 2017, the company announced partnerships with major pharmaceutical companies to negotiate lowering prescription drug costs.

GoodRx has deep relationships with major pharmacy chains, including Walgreens, Walmart, CVS Caremark, and Publix, to allow customers to use GoodRx discounts and Gold benefits. GoodRx began its partnership with CVS Caremark in July 2023 to automatically apply coupons to insured CVS customers purchasing generic prescriptions at certain locations. In April 2024, GoodRx added Publix into its network, allowing GoodRx Gold members to use their cards at Publix Pharmacies.

GoodRx partners with Pharmacy Benefit Management like Caremark, Express Scripts, and MedImpact to apply their savings directly to eligible insurance plans and members.

GoodRx partners with companies like Affirm, Benefitfocus, and DoorDash to integrate their services that offer members discounts and financial flexibility for prescriptions.

GoodRx also partners with organizations like the American Academy of Family Physicians Foundation to support broader access to care.

In October 2022, GoodRx launched Provider Mode, which allows healthcare providers to use the app to compare costs of drugs for patients based on different payment methods and drug alternatives.

In 2025, GoodRx partnered with Novo Nordisk to offer discounted cash-pay access to semaglutide products like Ozempic and Wegovy through its platform and participating pharmacies.

From Wikipedia’s article on GoodRx, shared under CC BY-SA 4.0.8

Leadership

Who has led GoodRx, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (25)

Products and brands

  • GoodRx app

Listed on Wikidata.1

GoodRx started its telemedicine service GoodRx Care in September 2019. It lets people talk to a licensed provider online for common issues and get prescriptions even if they don't have insurance.

They also run condition-specific subscription plans that bundle online doctor visits, FDA-approved meds, and home delivery into one monthly payment.

On the weight management side, GoodRx offers prescriptions for GLP-1 drugs like semaglutide through their telemedicine platform. This got a boost when the oral version of Wegovy became widely available in the US in early 2026.

GoodRx works with drug makers like Novo Nordisk to make some medications (including semaglutide options) more affordable for people paying cash.

Read the full text

The telemedicine part took off after GoodRx bought HeyDoctor in 2019 and brought their virtual care tools into the main platform.

From Wikipedia’s article on GoodRx, shared under CC BY-SA 4.0.8

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Buckeye Acquisition, LLC DBA RxNXT Delaware9
  • GoodRx Care, LLC FKA HeyDoctor, LLC Delaware9
  • GoodRx Intermediate Holdings, LLC Delaware9
  • GoodRx, Inc. Delaware9
  • HealthiNation Inc. Delaware9
  • Iodine, Inc. Delaware9
  • Lighthouse Acquisition Corp. Delaware9
  • Pharmacy Services, LLC Delaware9
  • Project Cannon, LLC Delaware9
  • RxSaver, Inc. Delaware9
  • ScriptDrop Acquisition, LLC Delaware9
  • Scriptcycle, LLC North Carolina9
  • VCRx Acquisition, LLC Delaware9
  • VitaCare Prescription Services, Inc. Florida9
  • flipMD, Inc. Delaware9

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Aug 5, 20268-K Results of operations48
  2. Aug 5, 20268-K Executive or director change49
  3. Jun 18, 20268-K Shareholder vote50
  4. May 6, 20268-K Results of operations51
  5. Apr 24, 20268-K Executive or director change52
  6. Apr 3, 20268-K Executive or director change53
  7. Mar 27, 20268-K Executive or director change54
  8. Mar 18, 20268-K Change of auditor55
  9. Mar 6, 20268-K Executive or director change56
  10. Feb 27, 20268-K Executive or director change57
  11. Feb 25, 20268-K Results of operations58
  12. Dec 12, 20258-K Executive or director change59
  13. May 5, 2023New chief executive Scott Wagner becomes CEO20
  14. Sep 23, 2020New chief executive Trevor Bezdek becomes CEO22
  15. Sep 23, 2020New chief executive Douglas Joseph Hirsch becomes CEO21
  16. Sep 23, 2020Went public Listed on NASDAQ1
  17. Sep 2011Founded Founded1

Calendar

Coming up

  1. Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.04 a share, on Nov 4, 2025.60

When it reported results

  1. Aug 5, 2026Reported quarterly or annual results48
  2. May 6, 2026Reported quarterly or annual results51
  3. Feb 25, 2026Reported quarterly or annual results58
  4. Nov 4, 2025Reported quarterly or annual results61
  5. Aug 6, 2025Reported quarterly or annual results62
  6. May 7, 2025Reported quarterly or annual results63
  7. Feb 27, 2025Reported quarterly or annual results64
  8. Nov 7, 2024Reported quarterly or annual results65

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

419 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 68 major events, 233 insider forms, 54 large holders, 44 other. The latest 20:

  1. Oct 15, 20264 EDGAR
  2. Oct 15, 20264 EDGAR
  3. Oct 15, 20264 EDGAR
  4. Sep 15, 20264 EDGAR
  5. Sep 15, 20264 EDGAR
  6. Aug 26, 2026SCHEDULE 13D/A EDGAR
  7. Aug 26, 20264 EDGAR
  8. Aug 21, 20264 EDGAR
  9. Aug 19, 2026144 EDGAR
  10. Aug 17, 20264 EDGAR
  11. Aug 17, 20264 EDGAR
  12. Aug 12, 20264 EDGAR
  13. Aug 12, 20263 EDGAR
  14. Aug 5, 20268-K EDGAR
  15. Aug 5, 202610-Q EDGAR
  16. Aug 5, 20268-K EDGAR
  17. Jul 16, 20264 EDGAR
  18. Jul 16, 20264 EDGAR
  19. Jul 16, 20264 EDGAR
  20. Jun 18, 20268-K EDGAR

The 419 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

45 open-market trades by officers, directors and large owners since October 2021: 5 buys and 40 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2026FRANCISCO PARTNERS IV-A, L.P.10% ownerSale1,296,177$3.50$4.5MForm 4
Aug 25, 2026FRANCISCO PARTNERS IV-A, L.P.10% ownerSale127,273$3.44$437.8KForm 4
Aug 24, 2026FRANCISCO PARTNERS IV-A, L.P.10% ownerSale143,594$3.46$496.8KForm 4
Aug 21, 2026Francisco Partners GP IV Management Ltd10% ownerSale274,717$3.50$961.5KForm 4
Aug 20, 2026Francisco Partners GP IV Management Ltd10% ownerSale447,259$3.52$1.6MForm 4
Aug 19, 2026Francisco Partners GP IV Management Ltd10% ownerSale471,975$3.53$1.7MForm 4
Oct 15, 2025SEA VII Management, LLC10% ownerSale23,771$4.00$95.1KForm 4
Sep 5, 2025SEA VII Management, LLC10% ownerSale16,016$4.05$64.9KForm 4
Jul 3, 2025Spectrum VII Co-Investment Fund, L.P.10% ownerSale10,677$4.80$51.2KForm 4
Jun 6, 2025Spectrum Equity VII, L.P.10% ownerSale10,677$4.09$43.7KForm 4
Sep 3, 2024SEA VII Management, LLC10% ownerSale10,677$7.86$83.9KForm 4
Aug 12, 2024Nabiey RominChief Accounting OfficerSale79,000$6.77$534.8KForm 4
Nov 30, 2023Wagner ScottDirectorBuy21,652$5.76$124.7KForm 4
Nov 29, 2023Wagner ScottDirectorBuy26,348$5.90$155.5KForm 4
Nov 28, 2023Wagner ScottDirectorBuy4,157$6.00$24.9KForm 4
Nov 17, 2023Wagner ScottDirectorBuy26,664$5.26$140.3KForm 4
Nov 16, 2023Wagner ScottDirectorBuy104,079$5.16$537.0KForm 4
Jan 3, 2022Idea Men, LLCDirectorSale2,600$33.05$85.9KForm 4
Jan 3, 2022Slutsky AndrewPresident, ConsumerSale35,829$32.40$1.2MForm 4
Dec 28, 2021Voermann KarstenChief Financial OfficerSale12,500$33.05$413.1KForm 4

All 45 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Wendy Barnes54$825.0K$23.4M82
2025Christopher McGinnis55$454.8K$8.7M82
2025Romin Nabiey$347.2K$1.3M82
2025Trevor Bezdek48$416.7K$971.6K82
2025Scott Wagner55$42.8K$856.8K82
2025Karsten Voermann$22.2K$280.3K82
2024Former Interim ChiefExecutive Officer$750.0K$9.8M82
2024Former Chief Financial Officer$450.0K$5.8M82
2024Chief Accounting Officer and Former$326.6K$942.6K82
2024Co-Chairman of the Board$500.0K$853.9K82
2023Former Interim ChiefExecutive Officer$511.5K$10.1M82
2023Interim Chief Financial Officer$311.2K$2.6M82
2023Former Chief Financial Officer$450.0K$902.2K82
2023Co-Chairman of the Board$500.0K$811.5K82

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Francisco Partners Management, LP60,078,184$173.0M47.9%No change
Ameriprise Financial Inc4,746,330$13.7M0.0%+290,570
Vanguard Capital Management LLC4,086,521$11.8M0.0%−174,995
Silver Lake Group, L.L.C.3,532,276$10.2M0.2%No change
Renaissance Technologies LLC3,245,738$9.3M0.0%−14,000
Vanguard Portfolio Management LLC3,208,264$9.2M0.0%−154,600
Petrus Trust Company, LTA3,098,559$8.9M0.8%No change
Dimensional Fund Advisors LP2,560,229$7.4M0.0%+109,088
Aqr Capital Management LLC2,326,080$6.7M0.0%+523,735
Jane Street Group, LLC2,313,184$6.7M0.0%+1,665,363
Prescott Group Capital Management, L.L.C.2,105,502$6.1M0.5%No change
BlackRock, Inc.1,857,708$5.4M0.0%−3,883
Technology Crossover Management X, Ltd.1,653,566$4.8M0.6%No change
Geode Capital Management, LLC1,171,369$3.4M0.0%+93,242
Northern Trust Corp904,290$2.6M0.0%+249,159
Stifel Financial Corp868,790$2.5M0.0%+151,391
Moore Capital Management, LP864,044$2.5M0.1%−665,371
Goldman Sachs Group Inc858,326$2.5M0.0%−199,635
Two Sigma Investments, LP742,181$2.1M0.0%+553,810
Nano Cap New Millennium Growth Fund L P740,000$2.1M1.6%No change
Universal- Beteiligungs- und Servicegesellschaft mbH738,833$2.1M0.0%+62,057
State Street Corp625,045$1.8M0.0%−386,144
Vanguard Fiduciary Trust Co587,886$1.7M0.0%+22,941
California State Teachers Retirement System584,872$1.7M0.0%+9,207
Charles Schwab Investment Management Inc553,844$1.6M0.0%−8,792

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 25, 2021Anthony E. Gonzalez, HouseBuy$100,001 - $250,000−188.4%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How GoodRx is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGoodRx Holdings, Inc.2
  • CIK0001809519
  • Employer ID (EIN)47-510439619
  • Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
  • Incorporated inDelaware19
  • Fiscal year endsDecember 312
  • Industry code (SIC)7374 Services-Computer Processing & Data Preparation2
  • SEC reviewing officeOffice of Technology, Division of Corporation Finance2
  • Business address2701 Olympic Boulevard, Santa Monica, CA 904042
  • Phone(855) 268-28222
  • Shares outstanding108,610,311 Common Class A shares; 233,964,187 Common Class B shares as of Feb 17, 202619
  • Public float$423.2M as of Jun 30, 202519
  • AuditorPricewaterhouseCoopers LLP, Los Angeles, California PCAOB ID 238; it also attests to the company’s internal control over financial reporting19
  • On EDGAR sinceApr 16, 20202
  • Filings580 in all: 4 (301), 8-K (75), 3 (28), SC 13G/A (23), 10-Q (18), SC 13G (17), 144 (14), SC 13D/A (11)2
    All 34 form types

    SCHEDULE 13D/A (11), CORRESP (8), DEFA14A (8), UPLOAD (8), S-8 (7), 10-K (6), DEF 14A (6), SC 13D (6), 5 (5), SCHEDULE 13G/A (5), ARS (4), 3/A (2), D (2), EFFECT (2), S-1/A (2), 4/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), S-1 (1), S-3 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2026
    Quarterly report (10-Q) Aug 5, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Aug 5, 2026

Securities registered for trading

ClassSymbolExchange
Class A common stock, $0.0001 par valueGDRXThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks GoodRx names in Item 1A of its 10-K filed Feb 26, 2026: 78 risks under these headings, as written.19

  • Our business involves significant risks, some of which are described below. You should carefully consider the risks and
  • uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. The risks and
  • uncertainties described below are not the only ones we face. Additional risk and uncertainties that we are unaware of or that
  • we deem immaterial may also become important factors that adversely affect our business. The realization of any of these
  • risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of
  • operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the
  • market price of our Class A common stock could decline and you could lose part or all of your investment.
  • Risks Related to Our Limited Operating History and Historical Growth Rates
  • Our limited operating history and our evolving business make it difficult to evaluate our future prospects and the
  • risks and challenges we may encounter.
  • Our historical growth rates may not be sustainable or indicative of future growth.
  • Our results of operations vary and may fluctuate significantly from period-to-period.
The other 67 risks
  • We may be unable to manage our future growth effectively, which could make it difficult to execute our business
  • Risks Related to Our Business
  • We may be unsuccessful in achieving broad market education and changing consumer purchasing habits.
  • We may be unable to continue to attract, acquire, and retain consumers, or may fail to do so in a cost-effective
  • We rely significantly on our prescription transactions offering and may not be successful in expanding or
  • maintaining our offerings within our markets, particularly the U.S. prescriptions market, or to other segments of the
  • healthcare industry.
  • negotiated by industry participants.
  • We generally do not control the categories and types of prescriptions for which we can offer savings or discounted
  • We rely on a limited number of industry participants.
  • We operate in a very competitive industry and we may fail to effectively differentiate our offerings and services
  • from those of our competitors, which could impair our ability to attract and acquire new consumers and retain
  • existing consumers.
  • Our estimated addressable market is subject to inherent challenges and uncertainties. If we overestimate the size
  • of our addressable market or the various markets in which we operate, our future growth opportunities may be
  • We calculate certain operational metrics using internal systems and tools and do not independently verify such
  • metrics. Certain metrics are subject to inherent challenges in measurement, and real or perceived inaccuracies in
  • such metrics may harm our reputation and negatively affect our business.
  • Our telehealth related products and services are dependent on our ability to maintain our relationship with our
  • telehealth provider network, including our affiliated professional entities, and the ability of such entities to recruit
  • qualified telehealth providers.
  • Negative media coverage could adversely affect our business.
  • We may be unable to successfully respond to changes in the market for prescription pricing, and may fail to
  • maintain and expand the use of GoodRx codes through our apps and websites.
  • We may be unable to maintain a positive perception regarding our platform or maintain and enhance our brand.
  • We are obligated to maintain effective internal control over financial reporting and any failure to maintain effective
  • internal controls may cause us to not be able to accurately report our financial condition or results of operations,
  • which may adversely affect investor confidence in our company and, as a result, the value of our Class A common
  • Use of social media, emails, and text messages may adversely impact our reputation, subject us to fines or other
  • penalties or be an ineffective source to market our offerings.
  • We rely on information technology to operate our business and maintain competitiveness, and must adapt to
  • technological developments or industry trends.
  • We depend on our information technology systems, and those of our third-party vendors, contractors, and
  • consultants, and any failure or significant disruptions of these systems, security breaches or loss of data could
  • materially adversely affect our business, financial condition and results of operations.
  • We use and may expand our use of AI and machine learning in our business and challenges with properly
  • managing their use could result in reputational harm, competitive harm and legal liability, and adversely affect our
  • results of operations.
  • Government regulation of the internet and e-commerce is evolving, and unfavorable changes or failure by us to
  • comply with these laws and regulations could substantially harm our business and results of operations.
  • Our business relies on email, mail, and other messaging channels and any technical, legal or other restrictions on
  • the sending of such correspondence or a decrease in consumer willingness to receive such correspondence could
  • adversely affect our business.
  • We face the risk of litigation resulting from unauthorized text messages sent in violation of the Telephone
  • Consumer Protection Act.
  • Actual or perceived failures to comply with applicable data protection, privacy and security, advertising and
  • consumer protection laws, regulations, standards, and other requirements could adversely affect our business,
  • financial condition and results of operations.
  • We may be unable to realize expected benefits from our restructuring and cost reduction efforts and our business
  • might be adversely affected.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • We rely on the performance of members of management and highly skilled personnel, and if we are unable to
  • attract, develop, motivate and retain well-qualified employees, our business could be harmed.
  • A pandemic, epidemic, or outbreak of an infectious disease in the United States, has and could in the future
  • adversely impact our business.
  • General economic factors, natural disasters, or other unexpected events may adversely affect our business,
  • financial performance and results of operations.
  • We may seek to grow our business through acquisitions of, or investments in, new or complementary businesses,
  • technologies or products, or through strategic alliances, and the failure to manage these acquisitions, investments,
  • or alliances, or to integrate them with our existing business, could have a material adverse effect on us.
  • Restrictions in our debt arrangements could adversely affect our operating flexibility, and failure to comply with
  • any of these restrictions could result in acceleration of our debt.
  • Our business depends on network and mobile infrastructure and our ability to maintain and scale our technology.
  • Any significant interruptions or delays in service on our apps or websites or any undetected errors or design faults
  • could result in limited capacity, reduced demand, processing delays, and loss of consumers.
  • We rely on third-party platforms such as the Apple App Store and Google Play App Store, to distribute our platform
  • and offerings.
  • We rely on software-as-a-service (“SaaS”) technologies from third parties.

Legal proceedings

The information required under this Item 3 is set forth in Note 13 within “Notes to Consolidated Financial Statements”

included in Part IV, Item 15 of this report and is incorporated herein by this reference.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82